Status:
WITHDRAWN
An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
Lead Sponsor:
Jazz Pharmaceuticals
Conditions:
Ebola Virus
Eligibility:
All Genders
2-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.
Eligibility Criteria
Inclusion
- Positive for Ebola virus RNA in plasma
- Subject must be able to ingest, absorb, and tolerate oral medication
- Subject must be willing to use adequate contraception during their participation
Exclusion
- \-
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02271347
Start Date
October 1 2014
End Date
January 1 2015
Last Update
February 2 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.